Phase 1A/1B dose-escalation and -expansion study to evaluate the safety, pharmacokinetics, food effects and antitumor activity of pamiparib in advanced solid tumours

MLA

Ganessan Kichenadasse, et al. “Phase 1A/1B Dose-Escalation and -Expansion Study to Evaluate the Safety, Pharmacokinetics, Food Effects and Antitumor Activity of Pamiparib in Advanced Solid Tumours.” British Journal of Cancer, vol. 126, Nov. 2021, pp. 576–85. EBSCOhost, https://doi.org/10.1038/s41416-021-01632-2.

APA

Ganessan Kichenadasse, Kathy Zhang, Zhiyu Tang, Linda Mileshkin, Jason D. Lickliter, Mark Voskoboynik, Hui K Gan, Michael Millward, & Maggie Zhang. (2021). Phase 1A/1B dose-escalation and -expansion study to evaluate the safety, pharmacokinetics, food effects and antitumor activity of pamiparib in advanced solid tumours. British Journal of Cancer, 126, 576–585. https://doi.org/10.1038/s41416-021-01632-2

Chicago

Ganessan Kichenadasse, Kathy Zhang, Zhiyu Tang, Linda Mileshkin, Jason D. Lickliter, Mark Voskoboynik, Hui K Gan, Michael Millward, and Maggie Zhang. 2021. “Phase 1A/1B Dose-Escalation and -Expansion Study to Evaluate the Safety, Pharmacokinetics, Food Effects and Antitumor Activity of Pamiparib in Advanced Solid Tumours.” British Journal of Cancer 126 (November): 576–85. doi:10.1038/s41416-021-01632-2.